IP Library Granted Patent US 6,875,598
Granted Patent B1
US 6,875,598 · App. 10/239,333 · Granted Apr 5, 2005

Histone deacetylase-8 proteins, nuclei acids, and methods for use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,875,598
App. No.
10/239,333
Granted
Apr 5, 2005
Kind
B1
Abstract

The present invention is directed to novel nucleic acids that encode novel HDAC proteins, which have an affect on chromating structure and transcription. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods of producing the polypeptides of the present invention. Further provided by the present invention are methods of identifying novel compositions which mediate HDAC8 and the use of such compositions in diagnosis and treatment of disease.

Claims (7)

1. An isolated nucleic acid molecule comprising a nucleic acid sequence as set forth in FIG. 1 (SEQ ID NO: 1).

2. An isolated nucleic acid molecule encoding an amino acid sequence as set forth in FIG. 1 (SEQ ID NO: 2).

3. An expression vector comprising the isolated nucleic acid molecule according to any one of claim 1 or 2 operably linked to regulatory sequences recognized by a host cell transformed with the nucleic acid molecule.

4. A transformed host cell comprising the nucleic acid molecule according to any one of claim 1 or 2 .

5. A transformed host cell comprising the vector of claim 3 .

6. A process for producing a histone deacetylase (HDAC) protein comprising culturing the host cell of claim 5 under conditions suitable for expression of said HDAC protein.

7. The process according to claim 6 , further comprising recovering said protein.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0377. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded May 17, 2016
From: OXFORD AMHERST CORPORATION; PHARMACYCLICS, INC.
To: PHARMACYCLICS, INC.
Reel/Frame 038722/0776 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0398. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME. Recorded May 17, 2016
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 038722/0849 →
MERGER Recorded Jul 16, 2015
From: OXFORD AMHERST CORPORATION
To: PHARMACYCLICS, INC.
Reel/Frame 036126/0377 →
MERGER AND CHANGE OF NAME Recorded Jul 16, 2015
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 036126/0398 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2009
From: AXYS PHARMACEUTICALS, INC.
To: PHARMACYCLICS, INC.
Reel/Frame 022529/0676 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2008
From: APPLERA CORPORATION
To: CELERA CORPORATION
Reel/Frame 021561/0124 →